CN102755285B - Hormone cream - Google Patents
Hormone cream Download PDFInfo
- Publication number
- CN102755285B CN102755285B CN 201210250421 CN201210250421A CN102755285B CN 102755285 B CN102755285 B CN 102755285B CN 201210250421 CN201210250421 CN 201210250421 CN 201210250421 A CN201210250421 A CN 201210250421A CN 102755285 B CN102755285 B CN 102755285B
- Authority
- CN
- China
- Prior art keywords
- emulsifiable paste
- consumption
- weight percentage
- methylprednisolone aceponate
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a hormone cream which is prepared from solid used as an oil phase matrix, a consistence regulator, a humectant, an emulsifier, a stabilizer and the balance of water, wherein active ingredients are dispersed into a suspension of the cream by a water suspension mode, and the suspension additive is also necessarily added.
Description
The application is application number 200710060219.0, and the applying date is December in 2007 27 days, the dividing an application of the Chinese patent application that denomination of invention is " a kind of Hormonic autacoid emulsifiable paste ".
Technical field
The present invention relates to a kind of Hormonic autacoid emulsifiable paste, especially relate to a kind of methylprednisolone aceponate emulsifiable paste.
Background technology
The methylprednisolone aceponate emulsifiable paste is a kind of of steroid, can suppress the reaction of inflammation and allergic skin, also suppress to add related reaction of rapid regeneration and cause symptom with Fine born of the same parents simultaneously, for example erythema, edema, thickization of skin, coarse the going down of skin surface, and alleviate the problems such as pruritus, burning sensation and pain.The methylprednisolone aceponate emulsifiable paste is current superpower external corticosteroid formulations, its curative effect all is better than known corticosteroid, and wherein the methylprednisolone aceponate emulsifiable paste is the efficient corticosteroid without the halogen family group, side effect is light, be a kind of can be for child's corticosteroid external preparation.
Methylprednisolone aceponate emulsifiable paste commodity are called Advantan, are German Schering Corp (Schering AG) exploitation listings.Upper in Advantan description (http://www.betterhealth.vic.gov.au/bhcv2/bhcmed.nsf/pages/cscad van/ $ File/cscadvan.pdf), we can see that its main component is: methylprednisolone aceponate 0.1%; Adjuvant: Ceraphyl 140 (decyl oleate), the glyceryl monostearate of 40-55% content (glycerol monosteartae 40-55%), cetearyl alcohol (cetostearyl alcohol), stearic (hard fat), caprylic/capric/myristic acid/glycerol stearate/(Softisan 378), polyoxyethylene stearate (40) ester (PEG-40-sterate), the glycerol of 85% content, Calcium Disodium Versenate, benzyl alcohol, butoben, purified water.
2005 editions appendix I F of Chinese Pharmacopoeia mention: ointment means medicine dissolution or is scattered in emulsion type substrate the uniform semi-solid external preparation formed; The substrate of ointment should be even, fine and smooth, is applied on skin or mucosa and answers nonirritant; Ointment should have suitable stickiness, easily coats on skin or mucosa, does not melt, and stickiness should be very little with seasonal variations.
Existing methylprednisolone aceponate emulsifiable paste is had relatively high expectations for substrate, substrate requires adjuvant more, comparatively complicated, some adjuvant source is less, as Ceraphyl 140 (decyl oleate) and caprylic/capric/myristic acid/glycerol stearate/(Softisan 378), these adjuvants are domestic not to be had at present, import price more expensive.In addition, existing methylprednisolone aceponate emulsifiable paste stickiness is inadequate, be put on skin, and because mobility is excessive, the scope that bad control is applied ointment, in the time of use, the amount of extruding is bad control also.
On Merck index, we can know as 17-hydroxy-11-dehydrocorticosterone a kind of, methylprednisolone aceponate is to be insoluble in water and the compound that is dissolved in organic solvent, in prior art, to prepare emulsifiable paste for this corticoid compound, generally that compound first is dissolved in to organic solvent, in propylene glycol or dimethyl sulfoxine, as the authentication code Triamcinolone Acetonide Acetate Urea emulsifiable paste that is H44024203, the Compound Dexamethasone Cream that authentication code is H44024204, but the stability for the active component of organic solvent sensitivity can have a certain impact, especially methylprednisolone aceponate is this has 17, the 17-hydroxy-11-dehydrocorticosterone of 21-dibasic acid esters, in the situation that be dissolved in the situation that ester exchange easily appears in organic solvent, can have a strong impact on the stability of the emulsifiable paste be mixed with.。
Summary of the invention
For overcoming the problems of the prior art, the invention provides a kind of brand-new methylprednisolone aceponate emulsifiable paste, with existing this like product Advantan emulsifiable paste of German Schering Corp, compare, what the substrate of this emulsifiable paste related to is all conventional adjuvant, cheaply be easy to get, cost is lower, and the emulsifiable paste made is even, fine and smooth, is applied to nonirritant on skin or mucosa; And suitable stickiness is arranged, and in the time of use, the ointment that squeezes out more easy to control, can control the dose squeezed out well, and while spreading upon on skin, the scope of coating more easy to control.In addition, preparation technology is comparatively advanced, and owing to having adopted active component suspension manner of formulation, quality is more stable, and the storage time is longer.
The invention provides a kind of brand-new methylprednisolone aceponate emulsifiable paste, formed by the solid as oil phase substrate, consistency modifiers, wetting agent, emulsifying agent, stabilizing agent and water, it is characterized in that being formed by the raw material of following percentage by weight:
As the methylprednisolone aceponate 0.05%～0.5% of active component, preferably 0.1%;
Solid as oil phase substrate, include but are not limited to stearic acid, one or more in paraffin, Cera Flava, higher alcohol, the monohydric alcohol that described higher alcohol is 16～22 carbon atoms, the preferred hexadecanol of solid in described oil phase and/or octadecanol, the consumption of described solid is 1%～15%;
As consistency modifiers, one or more in the vaseline included but are not limited to, liquid paraffin, vegetable oil, preferred vaseline and/or liquid Paraffin, the consumption of described consistency modifiers is 1%～40%, particularly preferably consumption is 5%～20%;
With the multicomponent alcoholics compound as wetting agent, include but are not limited to glycerol, propylene glycol, sorbitol, the consumption of described wetting agent is 1%～15%, preferably glycerine,
Stabilizing agent, preferably but be not limited only to Calcium Disodium Versenate, the consumption of stabilizing agent is 0.05%～3%;
And emulsifying agent, include but are not limited to the derivant of soap class emulsifying agent, polyoxyethylene ether, preferably as the glyceryl monostearate of soap class emulsifying agent and/or as the peregal A-20 of polyoxy ether class emulsifying agent, total consumption of described emulsifying agent is 1～18%, preferably soap class emulsifier emulsifiable paste weight is 1～10%, and polyoxy ether class emulsifier is 0.5%～8% of emulsifiable paste weight.
Described higher alcohol also plays the effect of surfactant in substrate simultaneously
And, as optional antibacterial, include but are not limited to one or more in benzyl alcohol, p-Hydroxybenzoate, the consumption of described antibacterial is 0.1～5%,
The active component methylprednisolone aceponate is distributed in emulsifiable paste in the mode of aqueous suspension, also need to add the suspendible auxiliary agent in described active component suspension, the suspendible auxiliary agent include but are not limited to polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, carboxymethyl cellulose and or its salt, carbomer in one or more; The consumption of described suspendible auxiliary agent is 0.1～5%, the preferably polyethylene ketopyrrolidine;
Surplus is water
Above-mentioned percentage by weight is with the emulsifiable paste weighing scale.
The compound method that the invention provides a kind of brand-new methylprednisolone aceponate emulsifiable paste is as follows:
(1) oil phase preparation: take solid, consistency modifiers, emulsifying agent heating and melting in oil phase substrate, temperature remains on 70-80 ℃; (whether scope can strengthen)
(2) water preparation: the humectant of going bail for, stabilizing agent and water are placed in container, heating, temperature remains on 70-80 ℃;
(3) close phase: the oil phase of step (1) preparation is poured in the water of step (2) preparation, stirred, maintain the temperature at 60～90 ℃, add optional antibacterial;
(4) principal agent suspension: active component, water, suspendible auxiliary agent are placed in to container, and stirring or ultrasonic, obtain the principal agent suspension;
(5) control temperature at 50-75 ℃, in the solution that adds step (3) to obtain the principal agent suspension obtained in step (4), the limit edged stirs, and is cooled to cream.
The invention provides a kind of brand-new methylprednisolone aceponate emulsifiable paste, its optimization formula is comprised of the raw material of following percentage by weight: methylprednisolone aceponate 0.1%, white vaseline 5-10%, octadecanol 5-8%, glyceryl monostearate 5%～10%, liquid paraffin 5%～10%, peregal A-20 1%～5%, glycerol 5%～10%, Calcium Disodium Versenate 0.05%～1%, benzyl alcohol 0.1～3%, polyvinylpyrrolidone 0.1%～3%, surplus is water
The methylprednisolone aceponate of mentioning in the methylprednisolone aceponate emulsifiable paste the invention provides and compound method, granularity is: particle size range is 0.01-50 μ m, preferably 0.1-30 μ m, most preferably 0.5-10 μ m.Directly use aqueous solution preparation suspension; and used the suspendible auxiliary agent to make the active component microgranule obtain good dispersion; not only avoid with an organic solvent dissolving methylprednisolone aceponate; prevented that active component from the shortcoming of degraded easily occurring; and, due to the use of suspendible auxiliary agent, when making active component obtain fine dispersion, also produced a kind of clathration; the active component microgranule has been produced to the protection effect, thereby made the stability of cream made by technical solution of the present invention better.
Brand-new methylprednisolone aceponate emulsifiable paste provided by the invention and existing this like product of German Schering Corp are compared, stickiness is suitable, by 4 batches of emulsifiable pastes of joining by the embodiment of the present invention 1～4 respectively, according to " two methods of Chinese pharmacopoeia version in 2005 are measured dynamic viscosity, adopt NDJ-1 type Rotary Viscosimeter, with No. 4 rotors, rotating speed is per minute 6 to turn.Test result is as table 1:
Two kinds of methylprednisolone aceponate emulsifiable paste viscosity test results of table 1
Two kinds of methylprednisolone aceponate emulsifiable paste viscosity test results of table 1
Result shows, the viscosity of homemade 4 batch samples is all suitable, and this suitable stickiness is the assurance that emulsifiable paste is not stratified, principal agent is not separated out.First our self-control sample is lower slightly relatively for clever Advantan commercial viscosimetry, so mobility is excessive, is not easy to control the coating scope.
Brand-new methylprednisolone aceponate emulsifiable paste provided by the invention and existing this like product of German Schering Corp are compared, and quality stability will be got well.We are according to " the study on the stability method of the ointment formulation that Chinese pharmacopoeia version in 2005 is two ones, to homemade brand-new methylprednisolone aceponate emulsifiable paste and the study on the stability that first clever Advantan commodity have carried out long-term and acceleration, sample is from embodiment 1～4, the emulsifiable paste that each embodiment makes and lot number are that the first clever Advantan emulsifiable paste of 23448C compares, every group of sample size is 20, specification is that 10g/ props up, mainly liquid content and related substance are detected, are detected according to following liquid phase chromatogram condition:
The a chromatographic column is selected the chromatographic column that octadecylsilane chemically bonded silica is filler
B be take methanol: water=7:3(volume ratio) mixed solution is mobile phase,
It is 243 nm that c detects wavelength
D flow velocity=1ml/min
Result of the test is as follows:
Two kinds of methylprednisolone aceponate emulsifiable paste long-time stability investigation results (content) of table 2 (n=20,
± s)
Two kinds of methylprednisolone aceponate emulsifiable paste long-time stability of table 3 are investigated result (related substance)
Two kinds of methylprednisolone aceponate emulsifiable paste accelerated stabilities investigation results (content) of table 4 (n=20,
± s)
Two kinds of methylprednisolone aceponate emulsifiable paste accelerated stabilities of table 5 are investigated result
" the ointment regulation that Chinese pharmacopoeia version in 2005 is two ones, the active component content scope is 90%-110%.The methylprednisolone aceponate emulsifiable paste sample made by the embodiment 1～4 of table 2 and 3 and first clever Advantan stability of cream Data Comparison can find: in first 24 months investigate, the content difference of comparing embodiment 1～4 self-control sample with the Advantan emulsifiable paste is significantly (P>0.05) not, and its related substances difference of comparing embodiment 1～4 sample with the Advantan emulsifiable paste also not significantly (P>0.05), and all within acceptability limit, but in 25-36 month, the content of Advantan emulsifiable paste sharply descends, in the time of 36 months, content only 80.01%, related substance is up to 15.32%, defective, content according to embodiment 1～4 self-control sample all keeps up to 98% left and right, with content, the related substance of corresponding Advantan emulsifiable paste, compare all there is significance (P<0.01) this absolutely proved that the emulsifiable paste made according to the embodiment of the present invention is than first clever Advantan stability of cream is good.In addition, layering, metachromatism, in long-time stability are investigated, all do not occur in the emulsifiable paste made by the present invention program.
By table 4 and 5 according to the homemade methylprednisolone aceponate emulsifiable paste of embodiment 1～4 sample and first clever Advantan emulsifiable paste accelerated stability Data Comparison can find: at high temperature under condition and high light, all samples content all slightly descends in time, its related substances all slightly rises in time, but making the content of sample, embodiment 1～4 compares with the Advantan emulsifiable paste that although difference does not have the former content of significance (P>0.05) and the latter generally exceeds 1% ~ 2% on year-on-year basis.Under super-humid conditions, the content of all samples and its related substances change less, illustrate under this condition, less for the stability of cream impact.The accelerated stability Data Comparison has shown, makes sample by oneself than first clever Advantan emulsifiable paste accelerated stability outline is good.In addition, layering, metachromatism, in accelerated stability is investigated, all do not occur in our 3 batch samples.
Brand-new methylprednisolone aceponate emulsifiable paste provided by the invention and existing this like product of German Schering Corp are compared, and quality stability will be got well.This mechanism wherein is not yet clear, possible reason: the present invention is in preparation methylprednisolone aceponate emulsifiable paste process, directly use the suspension of aqueous solution preparation major ingredient, the appropriate suspendible auxiliary agent added in preparation suspension process, produced the suitable clathration to the active component microgranule, thereby effectively prevented that major ingredient from the shortcoming of degraded easily occurring, and uses in prior art; In addition, the adjuvant of selecting is suitable, and reasonable mixture ratio is also the reason that the methylprednisolone aceponate stability of cream is good.
The specific embodiment
Below will by embodiment, the invention will be further described, these descriptions are not that content of the present invention is further limited.One skilled in the art will understand that the replacement that is equal to that technical characterictic of the present invention is done, or corresponding the improvement, within still belonging to protection scope of the present invention.
In the embodiment of the present invention, the granularity of the methylprednisolone aceponate as active component used all adopts 0.5 μ m to 10 μ m in most preferred technical scheme, and the aluminum pipe that the emulsifiable paste that all embodiment make all props up with 10g/ divides and packages spare.
Embodiment 1
By above proportioning accurate weighing, moisture is two parts: 500g and 257g, gets ready, and the emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, octadecanol, glyceryl monostearate, liquid paraffin, peregal A-20 is placed in container, is heated to melting, and temperature remains on 72 ± 2 ℃;
(2) water preparation: by above proportioning accurate weighing, get glycerol, Calcium Disodium Versenate and 500g water are placed in container, heating, and temperature remains on 70 ± 2 ℃;
(3) close phase: the oil phase of step (1) preparation is poured in the water of step (2) preparation, stirred, maintain the temperature at 75 ± 2 ℃, add benzyl alcohol;
(4) principal agent suspension: methylprednisolone aceponate, 257g water, polyvinylpyrrolidone are placed in to container, and stirring or ultrasonic, obtain the principal agent suspension;
(5) control temperature at 50 ℃, in the solution that adds step (3) to obtain the principal agent suspension obtained in step (4), the limit edged stirs, and is cooled to cream.Obtain methylprednisolone aceponate emulsifiable paste 1kg.
Embodiment 2
By above proportioning accurate weighing, moisture is two parts: 380g and 259g, gets ready, and the emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, octadecanol, hexadecanol, glyceryl monostearate, liquid paraffin, peregal A-20 is placed in container, is heated to melting, and temperature remains on 72 ± 2 ℃;
(2) water preparation: by above proportioning accurate weighing, get glycerol, Calcium Disodium Versenate and 380g water are placed in container, heating, and temperature remains on 70 ± 2 ℃;
(3) close phase: the oil phase of step (1) preparation is poured in the water of step (2) preparation, stirred, maintain the temperature at 75 ± 2 ℃, add benzyl alcohol;
(4) principal agent suspension: methylprednisolone aceponate, 259g water, polyvinylpyrrolidone are placed in to container, and stirring or ultrasonic, obtain the principal agent suspension;
(5) control temperature at 58 ℃, in the solution that adds step (3) to obtain the principal agent suspension obtained in step (4), the limit edged stirs, and is cooled to cream.Obtain methylprednisolone aceponate emulsifiable paste 1kg.
Embodiment 3
By above proportioning accurate weighing, moisture is two parts: 380g and 260g, gets ready, and the emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, octadecanol, glyceryl monostearate, liquid paraffin, peregal A-20 is placed in container, is heated to melting, and temperature remains on 77 ± 2 ℃;
(2) water preparation: by above proportioning accurate weighing, get glycerol, Calcium Disodium Versenate and 380g water are placed in container, heating, and temperature remains on 75 ± 2 ℃;
(3) close phase: the oil phase of step (1) preparation is poured in the water of step (2) preparation, stirred, maintain the temperature at 75 ± 2 ℃, add benzyl alcohol;
(4) principal agent suspension: methylprednisolone aceponate, 260g water, hydroxypropyl emthylcellulose are placed in to container, and stirring or ultrasonic, obtain the principal agent suspension;
(5) control temperature at 68 ℃, in the solution that adds step (3) to obtain the principal agent suspension obtained in step (4), the limit edged stirs, and is cooled to cream.Obtain methylprednisolone aceponate emulsifiable paste 1kg.
Embodiment 4
By above proportioning accurate weighing, moisture is two parts: 300g and 237g, gets ready, and the emulsifiable paste process for preparation is as follows:
(1) oil phase preparation:, get white vaseline, octadecanol, glyceryl monostearate, liquid paraffin, peregal A-20 is placed in container, is heated to melting, and temperature remains on 77 ± 2 ℃;
(2) water preparation: by above proportioning accurate weighing, get glycerol, Calcium Disodium Versenate and 300g water are placed in container, heating, and temperature remains on 75 ± 2 ℃;
(3) close phase: the oil phase of step (1) preparation is poured in the water of step (2) preparation, stirred, maintain the temperature at 75 ± 2 ℃, add benzyl alcohol;
(4) principal agent suspension: methylprednisolone aceponate, 237g water, hydroxypropyl emthylcellulose are placed in to container, and stirring or ultrasonic, obtain the principal agent suspension;
(5) control temperature at 75 ℃, in the solution that adds step (3) to obtain the principal agent suspension obtained in step (4), the limit edged stirs, and is cooled to cream.Obtain methylprednisolone aceponate emulsifiable paste 1kg.
Embodiment 5～8
The consumption of methylprednisolone aceponate is adjusted into to 5g, respectively according to the prescription of embodiment 1～4 and technique preparation emulsifiable paste, the methylprednisolone aceponate emulsifiable paste that to obtain active component content be 0.5%.
Claims (10)
1. take the emulsifiable paste that methylprednisolone aceponate is active component for one kind, it is characterized in that being formed by the raw material of following percentage by weight,
The consumption of methylprednisolone aceponate is 0.05%～0.5% by weight percentage;
The solid of oil phase substrate is selected from stearic acid, one or more in paraffin, Cera Flava, higher alcohol, and the monohydric alcohol that described higher alcohol is 16～22 carbon atoms, consumption is 1～15% by weight percentage;
Consistency modifiers is selected from one or more in vaseline, liquid paraffin, vegetable oil, and consumption is 1～40% by weight percentage,
Wetting agent is multicomponent alcoholics compound, is selected from glycerol, propylene glycol, sorbitol, and consumption is 1%～15% by weight percentage;
Stabilizing agent is selected from Calcium Disodium Versenate, and consumption is 0.05%～3% by weight percentage;
Emulsifying agent is glyceryl monostearate and/or peregal A-20, and consumption is 1～18% by weight percentage;
Described active component is distributed in emulsifiable paste in the mode of aqueous suspension,
Also need to add the suspendible auxiliary agent in described active component suspension, consumption is 0.1～5% by weight percentage, and described suspendible auxiliary agent is selected from one or more in polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, carboxymethyl cellulose and/or its salt, carbomer;
Surplus is water.
2. take the emulsifiable paste that methylprednisolone aceponate is active component for one kind, it is characterized in that being formed by the raw material of following percentage by weight,
The consumption of methylprednisolone aceponate is 0.05%～0.5% by weight percentage;
The solid of oil phase substrate is selected from stearic acid, one or more in paraffin, Cera Flava, higher alcohol, and the monohydric alcohol that described higher alcohol is 16～22 carbon atoms, consumption is 1～15% by weight percentage;
Consistency modifiers is selected from one or more in vaseline, liquid paraffin, vegetable oil, and consumption is 1～40% by weight percentage,
Wetting agent is multicomponent alcoholics compound, is selected from glycerol, propylene glycol, sorbitol, and consumption is 1%～15% by weight percentage;
Stabilizing agent is selected from Calcium Disodium Versenate, and consumption is 0.05%～3% by weight percentage;
Emulsifying agent is glyceryl monostearate and/or peregal A-20, and consumption is 1～18% by weight percentage;
Antibacterial, be selected from one or more in benzyl alcohol, p-Hydroxybenzoate, and the consumption of described antibacterial is 0.1～5%,
Described active component is distributed in emulsifiable paste in the mode of aqueous suspension,
Also need to add the suspendible auxiliary agent in described active component suspension, consumption is 0.1～5% by weight percentage, and described suspendible auxiliary agent is selected from one or more in polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl emthylcellulose, hydroxyethyl-cellulose, carboxymethyl cellulose and/or its salt, carbomer;
Surplus is water.
3. emulsifiable paste as claimed in claim 1 or 2, the solid that it is characterized in that described oil phase substrate is octadecanol and/or hexadecanol.
4. emulsifiable paste as described as claim 1 to 2, is characterized in that described consistency modifiers is vaseline and/or liquid Paraffin, and consumption is preferably 5%～20%.
5. emulsifiable paste as claimed in claim 1 or 2, is characterized in that described wetting agent is glycerol.
6. emulsifiable paste as claimed in claim 1 or 2, the particle size range that it is characterized in that described methylprednisolone aceponate is 0.01 μ m to 50 μ m.
7. emulsifiable paste as claimed in claim 1 or 2, the particle size range that it is characterized in that described methylprednisolone aceponate is 0.1 μ m to 30 μ m.
8. emulsifiable paste as claimed in claim 1 or 2, the particle size range that it is characterized in that described methylprednisolone aceponate is 0.5 μ m to 10 μ m.
9. as arbitrary described emulsifiable paste in claim 1 or 2, it is characterized in that described suspendible auxiliary agent is polyvinylpyrrolidone.
10. emulsifiable paste as claimed in claim 2, it is characterized in that formula is comprised of the raw material of following percentage by weight: methylprednisolone aceponate 0.1%, white vaseline 5-10%, octadecanol 5-8%, glyceryl monostearate 5%～10%, liquid paraffin 5%～10%, peregal A-20 1%～5%, glycerol 5%～10%, Calcium Disodium Versenate 0.05%～1%, benzyl alcohol 0.1～3%, polyvinylpyrrolidone 0.1%～3%, surplus is water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210250421 CN102755285B (en) | 2007-12-27 | 2007-12-27 | Hormone cream |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210250421 CN102755285B (en) | 2007-12-27 | 2007-12-27 | Hormone cream |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710060219A Division CN101468024B (en) | 2007-12-27 | 2007-12-27 | Hormone emulsifiable paste |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102755285A CN102755285A (en) | 2012-10-31 |
| CN102755285B true CN102755285B (en) | 2013-12-18 |
Family
ID=47050105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210250421 Active CN102755285B (en) | 2007-12-27 | 2007-12-27 | Hormone cream |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102755285B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103877118A (en) * | 2014-03-11 | 2014-06-25 | 天津金耀集团有限公司 | Medicine composition consisting of methylprednisolone aceponate and zinc oxide |
-
2007
- 2007-12-27 CN CN 201210250421 patent/CN102755285B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102755285A (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101468024B (en) | Hormone emulsifiable paste | |
| CN108420797B (en) | Vitamin D analogue preparation and preparation method thereof | |
| EP1295600B1 (en) | Medicament based on gestagens for dermal application comprising ascorbic acid and/or salts thereof | |
| JP2011504870A (en) | Novel composition in the form of a petrolatum-free ointment comprising a vitamin D derivative and optionally a steroidal anti-inflammatory agent | |
| HU221427B (en) | Solid pharmaceutical composition comprising an excipient capable of binding water and process for its production | |
| CN102861106A (en) | Preparation method of compound paracetamol and amantadine pellets | |
| CN106606476A (en) | Ibuprofen suspension drops and preparation method thereof | |
| CN112691075A (en) | Sertaconazole nitrate cream and preparation method thereof | |
| CN102755285B (en) | Hormone cream | |
| CN104666312A (en) | Preparation containing calcipotriol and betamethasone dipropionate | |
| JP6850371B2 (en) | Suspension of sustained release containing dezosin analog ester and method for producing the same | |
| CN111743854A (en) | Externally-applied pharmaceutical composition of hydrocortisone butyrate with viscosity control function | |
| CN111743853A (en) | External pharmaceutical composition of near-neutral hydrocortisone butyrate | |
| Asija et al. | Formulation & evaluation of voriconazole ointment for topical delivery | |
| CN108685856A (en) | Pediatric paracetamol granule and preparation method thereof | |
| CN108158992B (en) | Emulsifiable paste preparation containing alclometasone dipropionate | |
| CN114557975A (en) | Sustained release tablet containing exemestane, process and use | |
| Krishna et al. | Preparation and evaluation of mucoadhesive microcapsules of glipizide formulated with gum kondagogu: In vitro and in vivo | |
| WO2018096008A1 (en) | Composition comprising avermectin compounds without solid fatty substances | |
| CN103405780A (en) | Ointment containing tretinoin inclusion compound and clobetasol propionate and preparation method thereof | |
| CN105687206A (en) | A fusidic acid-betamethasone valerate cream medicine composition and a preparing method thereof | |
| CN103127139B (en) | Difluprednate topical external preparation | |
| Krishna et al. | Design and development of mucoadhesive microcapsules of Glipizide formulated with gum karaya | |
| CN105878184A (en) | Altrenogest nanometer emulsion and method for preparing same | |
| CN105853352B (en) | A kind of suspension composition and preparation method thereof containing pranoprofen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121031 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Pharmaceutical Industry Group Corp., Ltd. Contract record no.: 2015120000066 Denomination of invention: Hormonic autacoid emulsifiable paste Granted publication date: 20131218 License type: Fen Xuke Record date: 20150929 Application publication date: 20121031 Assignee: Tianjin Pharmaceutical Industry Group Corp., Ltd. Assignor: Tianjin Jinyao Group Co., Ltd. Contract record no.: 2015120000049 Denomination of invention: Hormonic autacoid emulsifiable paste Granted publication date: 20131218 License type: Common License Record date: 20150916 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Tianjin Pharmaceutical Industry Group Corp., Ltd. Assignor: Tianjin Jinyao Group Co., Ltd. Contract record no.: 2015120000049 Date of cancellation: 20170113 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Pharmaceutical Industry Group Corp., Ltd. Contract record no.: 2015120000066 Date of cancellation: 20170113 |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121031 Assignee: Pharmaceutical Co., Ltd. Tianjin Jin Yao Assignor: Tianjin Jinyao Group Co., Ltd. Contract record no.: 2017120000027 Denomination of invention: Hormonic autacoid emulsifiable paste Granted publication date: 20131218 License type: Common License Record date: 20170116 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model |